Affiliate disclosure
We earn a commission if you sign up with MEDVi through the links on this page. It did not buy a favourable review. This is a substantial rewrite of our December 2025 version, which rated MEDVi 4.1 and did not account for an FDA warning letter issued in February 2026. The rating has come down accordingly.
MEDVi is a US telehealth platform selling compounded GLP-1 medication — semaglutide and tirzepatide, in both weekly injection and daily tablet form — to cash-pay patients who want medically supervised weight treatment without in-person visits or brand-name prices. It is one of the larger operators in the category and, on customer sentiment alone, one of the best-liked: around 4.4 out of 5 across more than 11,000 Trustpilot reviews. It also holds an F rating from the Better Business Bureau and received an FDA warning letter in February 2026 for misbranding the very products it sells. Reconciling those two facts is what this review is for.
Overview
The corporate entity is MEDVi, LLC, based at 131 Continental Drive, Suite 305, Newark, Delaware — an address confirmed on the FDA's own correspondence. The company operates across several domains including medvi.org and medvi.io, which is worth knowing when you are trying to work out which reviews refer to which business.
The service itself is conventional for the category: a comprehensive online medical evaluation and virtual consultation, a treatment plan from a US-licensed physician, and medication shipped free to your door, with month-to-month pricing that includes unlimited provider messaging and 24/7 patient support. The distinguishing product feature is the oral tablet option for both semaglutide and tirzepatide, which puts it in a small group alongside TrimRx and Willow.
MEDVi Is Not MEDvidi
Two different companies with near-identical names both appear on this site. MEDVi — this review — is a GLP-1 weight-loss telehealth platform. MEDvidi is a separate mental health telehealth company that also offers weight consultations.
This is not a pedantic distinction. Complaints about one have been filed against the other, and review aggregators routinely mix them up, which means any rating you read for either name may be contaminated. If you are researching MEDVi, check that what you are reading refers to medvi.org or medvi.io and not medvidi.com.
MEDVi at a Glance
| Medications offered | Compounded semaglutide and compounded tirzepatide, as weekly injections or daily oral tablets; brand-name GLP-1s available on a separate membership |
|---|---|
| Brand-name or compounded | Compounded — not FDA-approved. Brand-name products are available under a different pricing structure |
| Consultation process | Comprehensive online medical evaluation plus a virtual consultation with a US-licensed physician |
| Eligibility | Assessed at evaluation; specific criteria are not published |
| Provider involvement | Unlimited provider messaging and 24/7 patient support included in the monthly price |
| Lab requirements | Not stated as required |
| Pharmacy fulfillment | Not named. The FDA found MEDVi's own labelling wrongly implied MEDVi was the compounder |
| Shipping frequency | Free, direct to the patient |
| Support services | 24/7 patient support; the company responds individually to almost all negative public reviews |
| Membership fees | None on compounded plans. Brand-name GLP-1s require a separate $99/month membership plus medication cost |
| Medication fees | Compounded semaglutide from about $179/month at entry dose; compounded tirzepatide from about $299/month |
| Cancellation policy | Month-to-month with no contract; cancellation timing is a recurring complaint |
| Refund policy | Not clearly published; refund and billing disputes are the leading complaint category |
| Insurance | Not accepted — this is a cash-pay service |
| HSA/FSA | Not clearly stated in published materials |
| Availability | Not published in detail; US only |
How It Works, Step by Step
- Online medical evaluation. A health questionnaire covering history and goals.
- Virtual consultation. A US-licensed physician reviews your case and builds a treatment plan.
- Choose format. Semaglutide or tirzepatide, injection or oral tablet.
- Payment. Month-to-month pricing, with the medication cost covering provider messaging and support.
- Compounding and delivery. An unnamed compounding pharmacy prepares the medication, shipped free to your door.
- Ongoing care. Unlimited provider messaging and 24/7 patient support for dose questions and side effects.
Pricing and the Month-Two Problem
Independent coverage of MEDVi in 2026 places compounded semaglutide at around $179 per month at the entry dose and compounded tirzepatide at around $299 per month, with free shipping and no membership fee on compounded plans. Brand-name GLP-1s are handled differently: a $99 per month membership plus the cost of the medication on top.
| Option | Reported price | Status | Notes |
|---|---|---|---|
| Compounded semaglutide | From ~$179/mo | Not FDA-approved | Entry dose; injection or tablet |
| Compounded tirzepatide | From ~$299/mo | Not FDA-approved | Injection or tablet |
| Brand-name GLP-1s | $99/mo membership + medication | FDA-approved | Medication cost not published |
Note the phrase "at entry dose". The single most common theme in MEDVi's BBB complaints is a price increase at month two — customers describing an initial rate that rose once they moved past the starting dose or the first billing cycle.
MEDVi markets month-to-month transparency, and on the first month that appears to hold. If you are budgeting, the number that matters is what you pay at a maintenance dose in month three, not what you pay to start. Ask for that figure explicitly before you sign up, and be aware that providers such as Precision Telemed and TrimRx commit in writing to a flat price at every dose.
The FDA Warning Letter
On 20 February 2026 the FDA's Center for Drug Evaluation and Research issued MEDVi, LLC a warning letter (reference 721455), published on the FDA's own website. It followed a December 2025 review of MEDVi's website content at medvi.io. There are two distinct findings, and both are worth reading in the agency's own words.
1. MEDVi's labelling implied it was the compounder. The FDA wrote: "The compounded semaglutide and tirzepatide products displayed on your website identify ‘MEDVi’ on the pictured label, suggesting MEDVi is the compounder of those drugs when in fact it is not." The agency concluded those representations were "false or misleading" and the products therefore misbranded.
2. Comparison claims implied FDA approval. The FDA identified the claims "Same active ingredient as Wegovy® and Ozempic®" and "Same active ingredient as Mounjaro® and Zepbound®" on MEDVi's site, and stated: "Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not."
The letter found the products misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act, and their distribution a prohibited act under section 301(a). It gave MEDVi fifteen working days to respond, and warned that failure to address the violations "may result in legal action without further notice, including, without limitation, seizure and injunction."
Three pieces of context matter for reading this fairly. First, the letter concerns marketing and labelling, not product safety — the FDA did not say MEDVi's medication was contaminated, misformulated or dangerous. Second, MEDVi was not singled out: the agency issued warning letters to more than 30 telehealth companies over similar compounded GLP-1 marketing violations in the same period, and this was an industry-wide enforcement sweep. Third, the FDA explicitly noted the cited claims "do not represent an exhaustive list of violations".
What it tells a buyer is still substantive. The "same active ingredient" framing is the central sales argument of the entire compounded GLP-1 industry, and the FDA has now said in writing that using it the way MEDVi did misleads people into thinking they are getting something FDA-evaluated. If you are choosing MEDVi partly because you believe its compounded semaglutide is functionally the same product as Wegovy, that belief is exactly what the regulator objected to. Our compounded vs brand-name guide sets out what actually differs.
The labelling finding is the more troubling of the two. A product picture carrying the MEDVi name, for a drug MEDVi does not compound, obscures precisely the link in the chain a patient most needs to be able to trace — and MEDVi still does not publicly name its compounding pharmacy.
Eligibility, Contraindications, and Side Effects
MEDVi assesses eligibility through its online evaluation and virtual consultation but does not publish BMI or comorbidity thresholds, nor a detailed list of states served. See our eligibility guide for what a proper screen covers.
Semaglutide and tirzepatide carry a boxed warning regarding thyroid C-cell tumours, based on rodent studies. You should not take these medications if you or a family member have had medullary thyroid carcinoma, if you have Multiple Endocrine Neoplasia syndrome type 2, or if you have had a serious hypersensitivity reaction to the active ingredient. They are not for use in pregnancy. A history of pancreatitis, gallbladder disease, gastroparesis or other severe gastrointestinal disease, or diabetic retinopathy, warrants specific discussion first.
Common side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation and abdominal pain — usually worst after a dose increase. Serious but less common risks include pancreatitis, gallbladder disease and acute kidney injury from dehydration. Choosing tablets over injections does not avoid them. One further point specific to compounded oral GLP-1s: the absorption of oral semaglutide is highly dependent on formulation, and a compounded tablet is not the same product as the FDA-approved oral formulation, which was specifically engineered for it. See our side effects guide.
We are not quoting weight-loss figures for MEDVi. Given the FDA letter specifically addressed claims transposing brand-name evidence onto compounded products, doing so would repeat the error the regulator identified.
Legitimacy and the Split Complaint Record
MEDVi's record is the widest split we have seen on this site, and it deserves to be laid out plainly rather than averaged into something meaningless.
Trustpilot: 4.4 / 5
Across more than 11,000 verified reviews — among the largest samples in the telehealth GLP-1 space, and among the highest scores. MEDVi also responds to nearly every negative review individually rather than with a template, which is genuinely uncommon.
BBB: F, not accredited
Complaints concentrate on the month-two price increase and cancellation timing. Billing and cancellation is the leading complaint category — ahead of medication concerns, side effects or clinical care quality.
An 11,000-review sample at 4.4 is not a rounding error, and it should not be dismissed. The most reasonable reading is that MEDVi delivers the core service — evaluation, prescription, medication, support — competently and at scale, and that the people who have a bad experience have it at the billing layer. That is the same pattern we see across this whole category; MEDVi's version is simply larger in both directions.
The FDA letter is the thing that stops us treating the Trustpilot score as decisive. Customer satisfaction measures whether people felt well served; it does not measure whether they were accurately informed about what they were buying. On the second question the regulator has answered, in writing, and not in MEDVi's favour.
How MEDVi Compares
| Provider | Semaglutide from | Price flat at every dose | Oral option | Names pharmacy | Our rating |
|---|---|---|---|---|---|
| MEDVi | ~$179 entry dose | No — complaints of month-two rises | Yes | No | 3.1 / 5 |
| TrimRx | $179 oral / $199 injectable | Yes | Yes | No | 3.4 / 5 |
| Embody | $69 advertised | Advertised, disputed | No | Yes | 3.3 / 5 |
| Cora Health | $99–$175 | Banded, with a published ceiling | No | Yes — PCAB | 4.5 / 5 |
TrimRx is the closest comparison — same oral-plus-injectable range, same entry price for the tablet — and it commits to a flat price at every dose, which is exactly the thing MEDVi's complaints are about. If the oral option is what draws you to MEDVi, TrimRx offers it with a firmer pricing promise. Cora Health is cheaper, names a PCAB-accredited pharmacy and publishes a price ceiling, but is injectable only.
Pros and Cons
Pros
- 4.4 / 5 across more than 11,000 Trustpilot reviews — a very large sample
- Responds individually to nearly every negative review
- Oral tablet option for both semaglutide and tirzepatide
- Compounded semaglutide from about $179 with no membership fee
- Free shipping
- Unlimited provider messaging and 24/7 patient support included
- Virtual consultation with a US-licensed physician, not just an async form
- Month-to-month with no contract
- Brand-name FDA-approved GLP-1s available as an alternative route
Cons
- FDA warning letter, 20 February 2026, for misbranded compounded products
- FDA found its labelling wrongly implied MEDVi was the compounder
- FDA found "same active ingredient" claims implied FDA approval
- F rating from the BBB, not accredited
- Billing and cancellation is the leading complaint category
- Widespread complaints of a price increase at month two
- Compounding pharmacy still not publicly named
- Advertised price applies at entry dose, not at maintenance
- Brand-name route adds a $99/month membership with unpublished medication cost
- Eligibility criteria and state coverage not published
- Easily confused with MEDvidi, contaminating third-party ratings
- Insurance not accepted
Who Should Pick It, and Who Should Look Elsewhere
MEDVi might suit you if you want a large, established operator with a genuinely strong customer-satisfaction record, you value a real virtual consultation and unlimited provider messaging, and you want the oral tablet option. The 11,000-review score is not marketing — it reflects a service that works for most of the people who use it. If you go ahead, get your maintenance-dose price in writing first and diarise your cancellation window.
Look elsewhere if a regulator citing your provider for misleading claims about the product you are buying would trouble you — a reasonable position, and this review's rating reflects it. Look elsewhere if you want a guaranteed flat price, where TrimRx and Precision Telemed commit to one. Look elsewhere if you want to know which pharmacy compounds your medication, where Cora Health and Embody both name theirs. And if the appeal is that compounded semaglutide is "the same as Wegovy", buy Wegovy — NovoCare Pharmacy sells the FDA-approved pill at $149, less than MEDVi charges for the compounded version.
Limitations of This Review
This review is based on the FDA's published warning letter, MEDVi's BBB profile, Trustpilot and independent coverage, checked on 6 August 2026. Pricing figures come from independent coverage rather than a published MEDVi price list we could verify directly, so treat them as indicative and get your own quote. We do not know what MEDVi told the FDA in its fifteen-day response, or whether the agency considers the matter closed — we could not find a published close-out letter, and its absence is not evidence either way. We have not signed up, been prescribed, or received medication. State coverage and eligibility criteria are not published. This review also corrects our December 2025 version, which rated MEDVi 4.1 before the warning letter was issued.
Frequently Asked Questions
Did MEDVi really get an FDA warning letter?
Yes. The FDA's Center for Drug Evaluation and Research issued MEDVi, LLC a warning letter dated 20 February 2026, published on fda.gov, finding its compounded semaglutide and tirzepatide products misbranded because its website wrongly implied MEDVi was the compounder and because "same active ingredient" claims implied FDA approval. It concerned marketing and labelling, not product safety.
Is MEDVi legit?
It is a real, large telehealth operator with more than 11,000 Trustpilot reviews averaging 4.4 and a US-licensed physician network. It also holds an F BBB rating and an FDA warning letter for misbranding. Legitimate as a business; not clean on regulatory compliance.
How much does MEDVi cost?
Reported at around $179/month for compounded semaglutide at the entry dose and around $299 for compounded tirzepatide, with free shipping and no membership on compounded plans. Brand-name GLP-1s require a $99/month membership plus medication. Ask what you will pay at a maintenance dose — month-two increases are the leading complaint.
Is MEDVi the same as MEDvidi?
No. MEDVi (medvi.org, medvi.io) is a GLP-1 weight-loss platform. MEDvidi (medvidi.com) is a separate mental health telehealth company. Complaints and reviews are frequently misattributed between the two.
Does the price go up as my dose increases?
Advertised rates are quoted at the entry dose, and price increases at month two are the most common complaint against MEDVi. It does not publish a flat-price-at-every-dose commitment the way TrimRx and Precision Telemed do.
Is MEDVi's semaglutide FDA-approved?
No. Its compounded semaglutide and tirzepatide are not FDA-approved. The FDA specifically warned MEDVi that claiming the "same active ingredient" as Wegovy, Ozempic, Mounjaro or Zepbound implied an approval that does not exist.
Verdict
3.1 / 5
One of the best-liked services in the category by its own customers, and one of the few with a federal warning letter on file for misdescribing what it sells — a combination that says the experience is good and the disclosure is not.
We have rated MEDVi down from 4.1 and the reason is entirely the regulatory record. On service, 11,000 reviews at 4.4 with individually written responses to complaints is a better showing than almost anything else on this site, and the oral tablet range is a real product advantage. But the FDA found MEDVi putting its own name on a label for a drug it does not compound, and selling compounded medication with language implying it had been FDA-evaluated. Those are not presentational slips; they go to what the customer thinks they are buying. Good service does not offset being told wrong.
Medical Disclaimer & Review Date
This review is general consumer information, not medical advice. GLP-1 medications are prescription drugs with serious contraindications, and whether any treatment is appropriate for you is a decision only a licensed healthcare provider who knows your medical history can make. Nothing here should be used to start, stop, or change a medication.
Details in this review come from MEDVi's own published materials as of the date below. Pricing, medication availability, state coverage, and policies in this category change frequently — verify current terms directly with the provider before purchasing.
Date reviewed: August 6, 2026
Ask for the Maintenance-Dose Price
The entry price is not the price. Before signing up, ask what you will pay at the dose you expect to maintain, and get it in writing.